Last updated: May 29, 2026

Application No. 17/764,193

4-AMINO-IMIDAZOQUINOLINE COMPOUNDS AND USE THEREOF

Non-Final OA

Filed

Mar 27, 2022

Priority

Oct 29, 2019 — provisional 62/927,354 +2 more

Examiner

HUTTER, GILLIAN A

Art Unit

1625

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Prime Reach Trading Limited

OA Round

3 (Non-Final)

Interview Optional

— +46.1% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 55% grant rate with +46.1% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 113 resolved cases, 2023–2026

Examiner Intelligence

HUTTER, GILLIAN A View full profile →

Grants 55% of resolved cases

Career Allowance Rate

62 granted / 113 resolved

-5.1% vs TC avg

Strong +46% interview lift

Without

With

+46.1%

Interview Lift

resolved cases with interview

Typical timeline

2y 11m

Avg Prosecution

36 currently pending

Career history

165

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

55.3%

+15.3% vs TC avg

§102

14.5%

-25.5% vs TC avg

§112

8.0%

-32.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 113 resolved cases

Prosecution Timeline

Show 2 earlier events

Jun 02, 2025

Response Filed

Sep 09, 2025

Final Rejection mailed

Nov 12, 2025

Examiner Interview Summary

Nov 12, 2025

Applicant Interview (Telephonic)

Nov 30, 2025

Response after Non-Final Action

Jan 30, 2026

Request for Continued Examination

Apr 20, 2026

Response after Non-Final Action

May 26, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/516,260

Patent 12606508

CANNABIS EXTRACTS AND USES THEREOF

2y 5m to grant Granted Apr 21, 2026

17/053,057

Patent 12582660

INHIBITORS OF THE RAS ONCOPROTEIN, METHODS OF MAKING AND METHODS OF USE THEREOF

5y 4m to grant Granted Mar 24, 2026

18/167,634

Patent 12582620

ORAL SOLUTIONS COMPRISING LISDEXAMFETAMINE SALTS

3y 1m to grant Granted Mar 24, 2026

16/960,851

Patent 12569494

COMPOSITIONS AND METHODS TO PROMOTE THYMIC REGENERATION

5y 8m to grant Granted Mar 10, 2026

17/430,188

Patent 12559463

CRYSTALLINE FORMS OF A JAK2 INHIBITOR

4y 6m to grant Granted Feb 24, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

55%

Grant Probability

99%

With Interview (+46.1%)

2y 11m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 113 resolved cases by this examiner. Grant probability derived from career allowance rate.